1. Home
  2. Analysis

Breast pain and drugs of ingredients of ethinyl estradiol; norgestrel (a real world drug study)


Summary:

Breast pain is found among people who take drugs with ingredients of ethinyl estradiol; norgestrel, especially for people who are female, 30-39 old , have been taking the drugs for 1 - 6 months. This phase IV clinical study is created by eHealthMe based on reports of 3,100 people who have side effects when taking drugs with ingredients of ethinyl estradiol; norgestrel from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Cryselle, Elinest, Lo/ovral, Lo/ovral-28, Low-ogestrel-21, Low-ogestrel-28, Norgestrel and ethinyl estradiol, Ogestrel 0.5/50-21, Ogestrel 0.5/50-28, Ovral, Ovral-28, Turqoz.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 28, 2026

3,100 people reported to have side effects when taking drugs with ingredients of ethinyl estradiol; norgestrel.
Among them, 22 people (0.71%) have Breast pain

What is Breast pain?

Breast pain is found to be associated with 977 drugs and 1,707 conditions by eHealthMe. Check the latest studies of Breast pain.

Number of reports submitted per year:

Could drugs with ingredients of ethinyl estradiol; norgestrel cause Breast pain?

Time on drugs with ingredients of ethinyl estradiol; norgestrel when people have Breast pain *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Breast pain when taking drugs with ingredients of ethinyl estradiol; norgestrel *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Breast pain when taking drugs with ingredients of ethinyl estradiol; norgestrel *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 9.09 %
  • 20-29: 45.45 %
  • 30-39: 45.45 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Heavy Or Prolong Menstrual Bleeding: 2 people, 9.09%
  2. Endometriosis (appearance of endometrial tissue outside the uterus and causing pelvic pain): 2 people, 9.09%
  3. Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 1 person, 4.55%
  4. Fibrocystic Breast Disease (a condition causing breast pain, cysts, and noncancerous breast lumps, affects many women): 1 person, 4.55%
  5. Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 4.55%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Plan B One-Step: 2 people, 9.09%
  2. Strattera: 1 person, 4.55%
  3. Imitrex: 1 person, 4.55%

Other side effects people have besides Breast pain *:

You may use this to check any potential undetected side effects.

  1. Mood Swings (an extreme or rapid change in mood): 6 people, 27.27%
  2. Heavy Or Prolong Menstrual Bleeding: 4 people, 18.18%
  3. Dysmenorrhea (painful menstruation): 4 people, 18.18%
  4. Vaginal Bleeding Between Periods: 4 people, 18.18%
  5. Menstrual Disorder (disease of menstrual cycle): 3 people, 13.64%
  6. Abdominal Pain: 3 people, 13.64%
  7. Muscle Spasms (muscle contraction): 3 people, 13.64%
  8. Menstruation Irregular: 1 person, 4.55%
  9. Nausea (feeling of having an urge to vomit): 1 person, 4.55%
  10. Gall Bladder Pain: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of ethinyl estradiol; norgestrel, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norgestrel. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.